Søren Lemonius
Chief Executive Officer bij Sunstone LSV & Co. Special Limited Partner III Holding ApS
Profiel
Søren Lemonius is a businessperson who has been the head of 9 different companies.
Presently, Mr. Lemonius holds the position of Managing Director at Betterinvest ApS, Managing Director at Sunstone LSV & Co. Special Limited Partner III Holding ApS and Managing Partner at Sunstone Capital A, Founding Partner of Sunstone Life Science Ventures A (a subsidiary of Sunstone Capital A).
He is also Director-Executive Board at Evolva SA and Founding Partner of Sunstone Life Science Ventures An and on the board of 12 other companies.
In the past Mr. Lemonius was Chairman at TD Vaccines A, Managing Director at Sunstone LSV Partners & Co. Holding III ApS, Managing Director at Sunstone LSV Partners Holding III ApS, Managing Director at Sunstone LSV Invest III Holding ApS, Managing Director at Sunstone LSV Invest III ApS, Managing Director at Sunstone LSV Special Limited Partner III Aps, Chairman of Biomonitor ApS, Chief Technology Officer at Strategic Investments A, Innovation Manager at Foss Analytical An and Investment Director at Vækstfonden.
Søren Lemonius received an undergraduate degree from the University of Southern Denmark.
Actieve functies van Søren Lemonius
Bedrijven | Functie | Begin |
---|---|---|
Sunstone Capital A/S
Sunstone Capital A/S Investment ManagersFinance Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors. | Private Equity Investor | 01-05-2007 |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Corporate Officer/Principal | 18-11-2009 |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Director/Board Member | - |
Sunstone LSV General Partner I ApS | Director/Board Member | - |
Sunstone LSV Special Limited Partner II Aps | Director/Board Member | - |
P/S Sunstone Biomedicinsk Venture III | Director/Board Member | - |
Sunstone LSV Management A/S | Director/Board Member | - |
Sunstone LSV Special LP II Holding Aps | Director/Board Member | - |
Sunstone LSV Gp I Holding ApS | Director/Board Member | - |
░░░░░░░░ ░░░ ░░░░░░░░ ░░░░░ ░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Eerdere bekende functies van Søren Lemonius
Bedrijven | Functie | Einde |
---|---|---|
░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░ ░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Søren Lemonius
University of Southern Denmark | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
STRATEGIC INVESTMENTS A/S | Miscellaneous |
GALECTO, INC. | Health Technology |
Bedrijven in privébezit | 36 |
---|---|
Foss Analytical A/S
Foss Analytical A/S Electronic Equipment/InstrumentsElectronic Technology Foss Analytical A/S engages in manufacturing and trading. The firm manufactures equipment for measuring, testing, and navigation. It wholesales other machinery and equipment. The company was founded on December 14, 1983 and is headquartered in Hillerød, Denmark. | Electronic Technology |
Biomonitor ApS
Biomonitor ApS Medical/Nursing ServicesHealth Services Biomonitor ApS conducts research and development focusing on developing bioassays to monitor patients’ response to biological therapeutics. It offers services in the field of biopharmaceuticals, patient monitoring services through measurement of drug levels and immunogenicity of biopharmaceuticals in patients under therapy of these drugs, and customized reporter-gene cell-based assay development. The company was founded by Klaus Bendtzen and Arsalan Kharazmi on October 30, 2003 and is headquartered in Herlev, Denmark. | Health Services |
Danmarks Eksport- og Investeringsfond
Danmarks Eksport- og Investeringsfond Investment ManagersFinance Danmarks Eksport- og Investeringsfond (EIFO) is a venture capital subsidiary of Government of Denmark and founded in 1992. The firm is headquartered in Hellerup, Denmark. | Finance |
Euro-Diagnostica AB
Euro-Diagnostica AB Pharmaceuticals: MajorHealth Technology Euro-Diagnostica AB provides autoimmunity testing and diagnostic solutions. It facilitates the development of safe and efficient drugs and optimal treatment of patients by providing cutting edge assays. The firm also provides clinical labs and physicians with tools to aid in diagnosis, prognosis, monitoring, and treatment of inflammatory and related diseases. The company was founded in 1992 and is headquartered in Malmo, Sweden. | Health Technology |
Atonomics A/S
Atonomics A/S Electronic Equipment/InstrumentsElectronic Technology Atonomics A/S provides diagnostic equipment for the biotechnology industries. Its product Atolyzer, is a microscopic biosensor that applies surface acoustic waves in the measurement of low levels of biomarkers in biological samples. The firm develops products for the benefit of health care professionals and patients. The company was founded by Thomas Warthoe, Peter Warthoe and Lars Bangsgaard on October 5, 2000 and is headquartered in Copenhagen, Denmark. | Electronic Technology |
ACE BioSciences ApS
ACE BioSciences ApS Pharmaceuticals: MajorHealth Technology ACE BioSciences A/S engages in the research and experimental development on biotechnology. It offers medical research, production, and sale of medical products. The company was founded on September 15, 2000 and is headquartered in Hillerød, Denmark. | Health Technology |
Nuevolution AB
Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Commercial Services |
Chempaq A/S
Chempaq A/S Medical SpecialtiesHealth Technology Chempaq was formed in 2001 by Ulrik Larsen who is the founder, based on Larsen idea to redefine the hematology test by creating a single use self contained cassette module. This PAQ (cassette) was designed to be easy to use automatically calibrated and to deliver high accuracy and precision. In February 2005, the Chempaq XBC was CE marked. Later in the same year in December, the Chempaq XBC received a 510(k) clearance from the FDA. Since 2005, Doctors offices and Hospitals have provided patients with a unique infection diagnosis using the Chempaq XBC product. | Health Technology |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Sunstone Capital A/S
Sunstone Capital A/S Investment ManagersFinance Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors. | Finance |
Evolva Biotech A/S | |
Sunstone LSV General Partner I ApS | |
TD Vaccines A/S
TD Vaccines A/S Pharmaceuticals: MajorHealth Technology TD Vaccines A/S S is a holding company that focuses on the development of vaccines to protect against travellers' diarrhoea (TD). It is a biotechnology company that discovers and develops novel vaccines to fight serious bacterial infections. Its lead programme is ACE527, an oral ETEC vaccine to protect against ETEC (Enterotoxigenic E Coli). Its oral combination vaccine, ACE920, designs to protect against ETEC and Campylobacter infections. The company was founded in November 2009 and is headquartered in Skorping, Denmark. | Health Technology |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Nuevolution A/S
Nuevolution A/S Miscellaneous Commercial ServicesCommercial Services Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark. | Commercial Services |
Sunstone LSV Special Limited Partner II Aps | |
P/S Sunstone Biomedicinsk Venture III | Finance |
Sunstone LSV Management A/S | |
Sunstone LSV Special LP II Holding Aps | |
Sunstone LSV Gp I Holding ApS | |
Sunstone Lsv Partners & Co. Holding ApS | |
Sunstone Lsv Partners Holding ApS | |
Sunstone LSV General Partner BI ApS | |
Sunstone LSV GP BI Holding ApS | |
Sunstone LSV Partners & Co. Holding III ApS | |
Sunstone LSV Partners Holding III ApS | |
Betterinvest ApS | |
Sunstone LSV Invest III Holding ApS | |
Sunstone LSV & Co. Special Limited Partner III Holding ApS | |
Sunstone LSV Invest III ApS | |
Sunstone LSV Special Limited Partner III Aps | |
Chempaq Patent Holding ApS | |
Sunstone Lsv Special Ltd. Partner Iii Holding Aps | |
Sunstone Life Science Ventures A/S
Sunstone Life Science Ventures A/S Financial ConglomeratesFinance Part of Sunstone Capital A/S, Sunstone Life Science Ventures A/S is a Danish company that provides investment services. The private company is based in Copenhagen, Denmark. | Finance |
Synendos Therapeutics AG
Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | Health Technology |